CCSD Code BH2: Pre-compounding test billing guide

Key takeaways

CCSD Code BH2 is the UK private healthcare billing code for a Pre Compounding Test, a check carried out before a compounded medicine, most often a chemotherapy preparation, is mixed by the pharmacy.

Pre-compounding checks exist because compounding is the most resource-intensive step in preparing a bespoke medicine, and confirming a patient is fit for the planned dose beforehand avoids preparing a compound that cannot then be given.

As with other CCSD codes, BH2’s exact schedule descriptor and billable status sit behind the login-gated CCSD Schedule of Procedures and should be verified there before a claim is submitted.

Pabau’s claims management software helps UK private oncology and specialist practices store CCSD codes, attach clinical documentation, and submit insurer claims with the correct coding from one system.

CCSD Code BH2 is the UK private healthcare billing code for a Pre Compounding Test, listed within the CCSD Schedule of Procedures maintained by the CCSD Group. It denotes a check carried out before a compounded medicine, most commonly a chemotherapy preparation, is mixed by the pharmacy.

This guide covers what a pre-compounding test involves, how the code fits into private medical insurance (PMI) billing, the documentation each claim needs, and the common errors that lead to rejected claims.

CCSD Code BH2: What a pre-compounding test is

A pre-compounding test is a check performed before a compounded medicine is prepared, confirming the patient remains fit for the planned dose before the pharmacy commits time and materials to mixing it.

Compounding, unlike dispensing a pre-manufactured drug, means preparing a bespoke formulation for an individual patient. A dose that cannot ultimately be given represents wasted drug, wasted pharmacist time, and in the case of cytotoxic or biologic agents, a meaningful cost.

In UK oncology, this pattern is well established: blood results taken close to the treatment date, typically full blood count and renal or liver function, are reviewed against the planned regimen before that cycle’s chemotherapy is compounded.

If the result falls outside the safe range for the regimen, the dose is adjusted, delayed, or withheld before compounding goes ahead rather than after.

CCSD Code BH2 sits within this type of pre-treatment verification step, a pattern also seen elsewhere in coding, such as the presumptive drug testing covered in Pabau’s CPT Code 80307 billing guide, where a result must be checked before a course of treatment can proceed.

Because the CCSD Schedule of Procedures sits behind a login-gated portal at ccsd.org.uk, the exact wording of the BH2 descriptor, the specialty chapter it sits in, and its current billable status should be confirmed directly against the schedule before a claim is submitted.

This guide explains the code’s function within UK private healthcare billing rather than reproducing the schedule’s own text, which is not publicly available without a CCSD login.

How CCSD codes are structured

CCSD codes are alphanumeric and organized into chapters, most of which follow anatomical body systems, alongside a smaller number of chapters organized by treatment type rather than anatomy. Chemotherapy is one of these treatment-type chapters, covering clinical supervision and planning for chemotherapy delivery rather than a specific body part.

Diagnostic and service-charge type entries, including tests, sit alongside procedural codes within the wider schedule structure, such as the surgical procedure covered in Pabau’s guide to CCSD Code Y3811 for complex pleural catheter removal. The CCSD Technical Guide sets out the business rules for how each code type is billed and combined.

Whether BH2 is billed as a standalone service charge or must accompany a related consultation or procedure code, in the way many diagnostic CCSD codes do, is a distinction worth confirming in the current schedule before submission, since it changes how the claim must be assembled.

For a worked example of a diagnostic-type CCSD code and how that distinction is handled in practice, see Pabau’s guide to CCSD Code 0019B, the Alpha Subunit test.

Where pre-compounding tests fit in clinical practice

Compounded medicines used in private practice fall into a few main categories: chemotherapy and other cytotoxic infusions, biologic and monoclonal antibody preparations, and specials made up for patients who cannot take a standard manufactured formulation.

Chemotherapy accounts for most of the volume, since almost every regimen is prepared to the patient’s current weight, body surface area, and blood results rather than dispensed off the shelf.

Newer biologic and monoclonal antibody infusions carry the same logic. Agents such as durvalumab, covered in Pabau’s billing guide for durvalumab (Imfinzi), or ocrelizumab, covered in the ocrelizumab (Ocrevus) billing guide, are high-cost preparations where a pre-treatment check protects against preparing an infusion that then cannot be given that day.

Practices running these services alongside general IV therapy services apply the same pre-treatment logic even outside oncology.

The clinical episode is typically coded alongside the underlying diagnosis driving treatment, such as a specific cancer diagnosis like ICD-10 Code C50.411 for right breast cancer, and the infusion or administration procedure itself.

Pabau’s chemotherapy IV infusion billing guide and the CCSD equivalent for intravenous infusion as a sole procedure cover how the administration itself is billed once the pre-compounding check has cleared the dose to proceed.

Documentation requirements for CCSD Code BH2

Every CCSD claim depends on documentation that supports the service billed. For a pre-compounding test, the patient record should show what was checked, when, and how the result affected the decision to proceed with compounding that cycle’s dose. Missing or incomplete records are a common reason insurers query oncology and infusion claims.

Core documentation required

• Treatment plan or regimen reference: The approved chemotherapy or infusion regimen the patient is on, including cycle number and planned dose.
• Test result and date: The specific pre-treatment result reviewed (for example, full blood count or renal function), with the date it was taken relative to the compounding and administration dates.
• Clinical decision recorded: A note confirming the result was reviewed and the dose was cleared, adjusted, or delayed as a result, made by the treating consultant or a delegated clinician.
• Pre-authorization reference: Obtained from the insurer before treatment where the insurer’s policy requires it for the regimen.
• Invoice detail: The invoice submitted to the insurer should state the CCSD code, the treating consultant, the facility, and the date of the check, alongside the codes for the related consultation or infusion.

These records sit under the same UK GDPR obligations as any other clinical record, and the CQC’s oversight of record standards in England means a weak documentation trail carries compliance exposure beyond the insurance claim itself.

Pabau’s digital patient intake software lets practices capture structured pre-treatment results using a template such as the IV therapy patient intake template, attach them to the patient’s record, and retrieve them at the point of invoice generation, so the evidence behind a BH2 claim is stored alongside the episode rather than tracked separately.

Insurer applicability: Which PMI providers accept CCSD Code BH2

CCSD codes are the standard reference across UK private medical insurance, and every major PMI provider bills against the same schedule. Recognition of the code does not mean a fixed reimbursement: each insurer sets its own fee independently and updates it periodically.

Never state a specific reimbursement figure on an invoice unless it has been confirmed from the insurer’s most recently published schedule. Oncology and specialist infusion claims often also require pre-authorization before the treatment cycle, so confirm the authorization route in addition to the fee before treating.

For a broader reference on how Bupa applies CCSD codes across its entire schedule, see Pabau’s Bupa CCSD codes guide. Practices seeing patients referred through private GP referral pathways should also confirm the authorization route at the point of referral, since it can differ from a direct consultant-led episode.

Manage CCSD claims without the paperwork overhead

Pabau helps UK private practices store procedure codes, attach clinical documentation, and submit insurer claims accurately from one platform. See how it works for your practice.

Book a demo

Billing and coding conventions for CCSD Code BH2

The CCSD Technical Guide sets out the coding conventions that apply across the schedule, including how codes are combined and what constitutes a complete billable episode. These rules apply to BH2 as they do to every other code in the schedule.

Combining BH2 with other codes

A pre-compounding test supports a treatment episode; it does not replace the codes for the consultation, the chemotherapy or infusion administration, or the underlying diagnosis. Most claims involving BH2 will include it alongside these related codes rather than as a standalone line.

Submitting BH2 without an accompanying treatment episode code is likely to prompt a query, since the check has no independent clinical purpose outside the compounding decision it supports.

Repeat cycles and recurring checks

Chemotherapy and long-term infusion regimens run over multiple cycles, and a pre-compounding test is typically repeated before each cycle rather than billed once for the whole course. Each occurrence needs its own supporting result and clinical decision in the record, dated to that specific cycle, rather than a single blanket note covering the regimen.

Schedule updates and code validity

The CCSD Group publishes bulletins when codes are added, amended, or retired. Practices should confirm that BH2 remains active in the current schedule version before submitting a claim, since using a retired or superseded code results in automatic rejection.

Common coding errors with CCSD Code BH2 and how to avoid them

Most rejections on pre-compounding and other service-charge codes follow predictable patterns. Knowing them in advance is the fastest route to a clean first-submission rate.

• Submitting BH2 without a treatment episode code: A pre-compounding test billed on its own, without the consultation, infusion, or procedure code it supports, is likely to be queried.
• Missing pre-authorization: Many PMI insurers require prior approval for chemotherapy and specialist infusion regimens. A claim submitted without a valid reference is likely to be rejected regardless of clinical appropriateness.
• No dated result on file: Billing the check without a dated test result and clinical decision recorded against that specific cycle weakens the claim if the insurer queries it.
• Blanket documentation across a regimen: A single note covering an entire course, rather than one result and decision per cycle, does not support repeated billing of BH2 across multiple appointments.
• Stale code usage: Submitting a code that was amended or retired in a recent CCSD bulletin without checking the current schedule version first.
• Mismatched consultant details: The GMC number on the invoice not matching the treating or supervising consultant in the clinical record, a frequent trigger for insurer audit requests.

For practices managing this level of detail across multiple consultants and treatment cycles, keeping a procedure code audit trail is particularly useful. Pabau’s claims management software lets practices attach clinical records directly to each billing episode, so the documentation behind CCSD Code BH2 sits with the claim rather than in a separate system that has to be reconciled by hand.

How to submit a claim using CCSD Code BH2

Claim submission for UK PMI insurers follows a broadly consistent workflow, though insurer-specific portals and electronic submission requirements vary. The steps below reflect standard practice for oncology and specialist infusion billing across the major PMI providers.

1. Confirm pre-authorization: Before the treatment cycle, contact the insurer with the patient’s membership number and the planned regimen. Record the authorization reference in the patient file.
2. Complete the pre-compounding check: Review the relevant test result against the planned dose, record the clinical decision, and confirm the compounding order can proceed for that cycle.
3. Prepare the invoice: Include the CCSD Code BH2 alongside the codes for the consultation, infusion, or procedure it supports, the consultant’s name and GMC number, the facility, and the date of the check.
4. Submit via Healthcode or insurer portal: Most UK PMI insurers accept electronic submission via Healthcode, the industry’s private healthcare billing network. Some also accept submission through their own portals.
5. Track and follow up: Monitor the claim status. If the insurer requests supporting documentation, respond within the timeframe set out in your provider agreement.

Practices managing multiple consultants and recurring treatment cycles benefit from a centralized billing record that shows, at a glance, which claims are submitted, pending, or need additional documentation. Manual spreadsheet tracking is a common cause of billing delays in oncology and infusion practices specifically, where claims recur every few weeks per patient.

Pabau’s roundup of the best medical billing software in the UK covers what to look for when choosing a system built for this kind of recurring claim volume.

How Pabau supports CCSD billing workflows

Pabau is practice management software built for UK and international private healthcare providers. For practices running chemotherapy, infusion, or other compounded-medicine services, it provides a structured environment for storing procedure codes, attaching clinical documentation, and managing the full billing cycle from consultation to claim resolution.

Key capabilities relevant to CCSD Code BH2 billing:

• Centralized patient records: Test results, treatment plans, and cycle-by-cycle clinical decisions are stored in the patient record and accessible at the point of invoice generation.
• Procedure code storage: CCSD codes including BH2 can be stored and attached to appointments, reducing manual entry and the risk of submitting a check code without its related treatment episode code.
• Consultant-level tracking: Claims are tracked by treating consultant, helping practice managers monitor first-submission rates and spot recurring rejection patterns by code or clinician.
• Integration with practice workflows: Booking, documentation, and billing sit in one platform, removing the need to reconcile data between separate systems when an insurer requests supporting evidence for a chemotherapy or infusion claim.

For practices transitioning from NHS to independent practice and building an oncology or infusion service from scratch, having one platform that connects the clinical episode to the billing record is the most practical way to reduce the administrative overhead that compounded-medicine billing can generate.

Reviewing data protection best practices alongside this setup helps keep sensitive treatment records compliant from day one.

Conclusion

CCSD Code BH2 follows the same billing logic as other CCSD service and diagnostic codes: it supports a treatment episode rather than standing alone, the documentation must show the result reviewed and the decision made before compounding went ahead, and the insurer’s pre-authorization and submission requirements must be met before the claim goes out.

Because the CCSD Schedule sits behind a login-gated portal, always confirm the code’s exact descriptor and billing rules against the current schedule before submission.

Pabau’s claims management tools give UK private oncology and specialist practices the structure to handle CCSD billing accurately from first appointment to final reimbursement. To see how it fits your workflow, book a demo with our team.

Continue your research

Billing a chemotherapy infusion alongside a pre-compounding check? Chemotherapy IV infusion billing guide covers how the administration itself is coded once the dose is cleared.

Need a complete reference for Bupa’s CCSD code set? Bupa CCSD codes guide covers the full schedule, denial patterns, and electronic submission process for Bupa claims.

Handling another CCSD diagnostic code? CCSD Code 0019B: Alpha subunit test guide walks through how a comparable service-charge code is billed and documented.

Frequently Asked Questions